Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

Kanis, J. A., Barton, I. P., Johnell, O. · 2005 · Osteoporosis International

Abstract

The aim of this study was to examine the effects of risedronate (5 mg/daily) in patients identified solely on the basis of a prior fragility fracture, without BMD as an inclusion criterion. A total of 1,802 patients were examined from the VERT-NA and VERT-MN clinical trials. Lateral radiographs (T4 to L4) were obtained at baseline and annually; incident fractures were evaluated using quantitative and semiquantitative methods at the central facility. BMD was measured at the lumbar spine and femoral neck by dual-energy X-ray absorptiometry. Secondary analyses evaluated vertebral fracture efficacy in patient subgroups categorized according to the presence of risk factors for osteoporosis at baseline (age, femoral neck BMD, lumbar spine BMD, more severe BMD, height, weight, body mass index, prevalent nonvertebral fracture status, smoking, and bone turnover marker levels). Over 3 years, risedronate reduced the risk of new vertebral fractures by 44% (95% CI, 28% to 56%) compared with placebo. In patients subgrouped according to the presence or absence of putative risk factors, the efficacy of risedronate was comparable across all groups (all treatment-by-non BMD subgroup interactions p > or =0.210). Adjustment for age, baseline BMD, and prevalent vertebral fractures on fracture risk gave results similar to the unadjusted analysis. In patients taking placebo, the incidence of new vertebral fracture was higher in several of the high-risk categories (elderly, T-score < or = -2.5 SD).…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00198-004-1698-y

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 40 · Cited by 108

Metadata

Authors
Kanis, J. A., Barton, I. P., & Johnell, O.
Affiliations
  • University of Sheffield (GB)
  • Procter & Gamble (United Kingdom) (GB)
Corresponding author
Kanis, J. A.
Venue
Osteoporosis International
Published
2004-07-23
Volume
16
Issue
5
Pages
475-482
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
OpenAlex
W2012044560
Cited by
108
References
40
Citations by year
2025: 2 · 2024: 1 · 2023: 8 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 6 · 2012: 5
FWCI
7.16
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Osteoporosis International (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
risedronate, vertebral fractures, fragility fractures, osteoporosis, bisphosphonates, fracture risk reduction, bone mineral density, subgroup analysis
MeSH terms
Risedronic Acid, Aged, Anthropometry, Double-Blind Method, Female, Femur Neck, Humans, Lumbar Vertebrae, Middle Aged, Recurrence, Risk Factors, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. https://app.cochat.ai/papers/10.1007/s00198-004-1698-y
The paper
Kanis, J. A., Barton, I. P., & Johnell, O. (2005). Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporosis International. https://doi.org/10.1007/s00198-004-1698-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.